HDAC4 and chronic kidney disease: These findings identify HDAC4 as a key mediator linking IR injury to ferroptosis and fibrotic progression, suggesting that targeting the HDAC4–Foxo3a axis may provide a novel therapeutic strategy to prevent the AKI–CKD transition.